Fisher et al33 Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(08):567-575. Doi: 10.1056/NEJMoa020128 https://doi.org/10.1056/NEJMoa020128...
|
1971–1974 |
25 years |
Radical mastectomyTotal mastectomyTotal mastectomy + radiotherapy |
1,079 |
Fisher et al55 Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing totalmastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347(16):1233-1241. Doi: 10.1056/NEJMoa022152 https://doi.org/10.1056/NEJMoa022152...
|
1976–1984 |
20 years |
Total mastectomyLumpectomyLumpectomy + radiotherapy |
1,851 |
Veronesi el al66 Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-1232. Doi: 10.1056/NEJMoa020989 https://doi.org/10.1056/NEJMoa020989...
|
1973–1980 |
20 years |
Radical mastectomyQuadrantectomy + radiotherapy |
701 |
van Dongen et al77 van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term results of a randomized trial comparing breastconserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92(14):1143-1150. Doi: 10.1093/jnci/92.14.1143 https://doi.org/10.1093/jnci/92.14.1143...
|
1980–1986 |
10 years |
Modified mastectomyLumpectomy + radiotherapy |
868 |
Poggi et al88 Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer. 2003;98(04):697-702. Doi: 10.1002/cncr.11580 https://doi.org/10.1002/cncr.11580...
|
1979–1987 |
18.4 years |
Modified mastectomyLumpectomy + radiotherapy |
237 |
Blichert-Toft et al99 Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, Andersen KW, et al; Danish Breast Cancer Cooperative Group. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. J Natl Cancer Inst Monogr. 1992;(11):19-25
|
1983–1989 |
6 years |
MastectomyLumpectomy + radiotherapy |
905 |
Arriagada et al1010 Arriagada R, Lê MG, Rochard F, Contesso G; Institut Gustave- Roussy Breast Cancer Group. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with15 years of follow-up data. J Clin Oncol. 1996;14(05):1558- -1564. Doi: 10.1200/JCO.1996.14.5.1558 https://doi.org/10.1200/JCO.1996.14.5.15...
|
1972–1979 |
15 years |
MastectomyConservative surgery + radiotherapy |
179 |
Fisher et al1111 Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88(21):1529- -1542. Doi: 10.1093/jnci/88.21.1529 https://doi.org/10.1093/jnci/88.21.1529...
|
1982–1988 |
10 years |
TamoxifenPlacebo |
2,818 |
Fisher et al1212 Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996;14(07):1982- -1992. Doi: 10.1200/JCO.1996.14.7.1982 https://doi.org/10.1200/JCO.1996.14.7.19...
NSABP 13 NSABP 19 |
|
8 years |
NSABP 13:Methotrexate + fluorouracilPlaceboNSABP 19:Cyclophosphamide + methotrexate + fluorouracilMethotrexate + fluorouracil |
7601,095 |
Haviland et al1919 Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al; START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086- -1094. Doi: 10.1016/S1470-2045(13)70386-3 https://doi.org/10.1016/S1470-2045(13)70...
START A START B |
1999–2002 |
10 years |
START A:25 radiotherapy fractions (50Gy)13 radiotherapy fractions (41.6 or 39 Gy)START B:25 radiotherapy fractions (50 Gy)15 radiotherapy fractions (40 Gy) |
2,2362,215 |
Hughes et al2020 Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-termfollow-up of CALGB 9343. J Clin Oncol. 2013;31 (19):2382-2387. Doi: 10.1200/JCO.2012.45.2615 https://doi.org/10.1200/JCO.2012.45.2615...
|
1994–1999 |
10 years |
≥ 70 years:LumpectomyLumpectomy + radiotherapy |
636 |
Kunkler et al2121 Kunkler IH,Williams LJ, Jack WJL, Cameron DA,Dixon JM; PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16 (03):266-273. Doi: 10.1016/S1470-2045(14)71221-5 https://doi.org/10.1016/S1470-2045(14)71...
|
2003–2009 |
5 years |
≥ 65 years:LumpectomyLumpectomy + radiotherapy |
1,326 |
Krag et al2424 Krag DN, Anderson SJ, Julian TB, Brown AM, HarlowSP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10): 927-933. Doi: 10.1016/S1470-2045(10)70207-2 https://doi.org/10.1016/S1470-2045(10)70...
|
1999–2004 |
8 years |
Negative sentinel lymph node:Sentinel lymph node aloneSentinel lymph node + axillary lymph node dissection |
5,611 |
Giuliano et al2525 Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(03):426-432, discussion 432-433. Doi: 10.1097/ SLA.0b013e3181f08f32 https://doi.org/10.1097/...
|
1999–2004 |
6.3 years |
Positive sentinel lymph node (1 or 2):Sentinel lymph node aloneSentinel lymph node + axillary lymph node dissection |
891 |
Donker et al2626 Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 noninferiority trial. Lancet Oncol. 2014;15(12):1303-1310. Doi:10.1016/S1470-2045(14)70460-7 https://doi.org/10.1016/S1470-2045(14)70...
|
2001–2010 |
5 years |
Positive sentinel lymph node:Axillary radiotherapySentinel lymph node + axillary lymph node dissection |
1,425 |
Sávolt et al2727 Sávolt A, Musonda P, Mátrai Z, Polgár C, Rényi-Vámos F, Rubovszky G, et al. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial]. Orv Hetil. 2013;154(49):1934-1942. Doi: 10.1556/OH.2013.29765 https://doi.org/10.1556/OH.2013.29765...
|
2002–2009 |
5 years |
Positive sentinel lymph node:Axillary radiotherapySentinel lymph node + axillary lymph node dissection |
526 |
Galimberti et al2828 Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al; International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(04):297-305. Doi: 10.1016/S1470-2045(13)70035-4 https://doi.org/10.1016/S1470-2045(13)70...
|
2001–2010 |
5 years |
Positive sentinel lymph node (micrometastases):Sentinel lymph node aloneSentinel lymph node + axillary lymph node dissection |
934 |
Solá et al2929 Solá M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results fromthe multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013;20(01):120-127. Doi: 10.1245/s10434-012-2569-y https://doi.org/10.1245/s10434-012-2569-...
|
2001–2008 |
5 years |
Positive sentinel lymph node (micrometastases):Sentinel lymph node aloneSentinel lymph node + axillary lymph node dissection |
247 |
Masuda et al3434 Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147-2159. Doi: 10.1056/ NEJMoa1612645 https://doi.org/10.1056/...
|
2007–2012 |
5 years |
HER2-negative invasive residual disease:CapecitabinePlacebo |
910 |
von Minckwitz et al3535 von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(07):617-628. Doi: 10.1056/NEJMoa1814017 https://doi.org/10.1056/NEJMoa1814017...
|
2013–2015 |
3 years |
HER2-positive invasive residual disease:TrastuzumabT-DM1 |
1,486 |